Propeller Health will co-package the Propeller digital health platform with Novartis’  Enerzair Breezhaler, a recently approved medication developed to treat uncontrolled asthma, the company announced today.

According to a release, the medication, sensor and app received approval from the European Commission this month and will launch across Europe starting this year. 

“Our collaboration with Novartis to co-package Propeller with Enerzair Breezhaler is the first time a pharmaceutical company and digital health company have worked together to package a digital health platform with an asthma medication,” Propeller Health CEO David Van Sickle said in a statement. “The ability to prescribe a maintenance medication with Propeller will make it easier for healthcare professionals to engage their patients in self-management.”

European healthcare professionals will have the option to prescribe the medication with or without the companion digital health platform.

The medication is not available in the United States.